Antiphospholipid Syndrome (APS) Market Size, Share, Trends, Growth, Key Companies, Emerging Drugs and Epidemiology Forecast

Antiphospholipid Syndrome (APS) is an autoimmune disorder in which the immune system misguidedly creates antibodies that make one’s blood substantially more likely to clot. It is also known as Hughes syndrome or lupus anticoagulant syndrome. Those with APS make abnormal proteins known as antiphospholipid autoantibodies (aPL) in the blood. This causes blood to flow improperly and can prompt to dangerous clotting in arteries and veins, problems for a developing fetus, and pregnancy miscarriage.

Currently, there is no cure for APS, however, standard initial treatment involves a combination of blood-thinning medications. The most common are heparin and warfarin. Heparin is fast-acting and delivered via injections.

Get FREE sample copy at: https://www.delveinsight.com/sample-request/antiphospholipid-syndrome-aps-market

View Report: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market

DelveInsight’s “Antiphospholipid Syndrome (APS) Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Antiphospholipid Syndrome (APS), historical and forecasted epidemiology as well as the Antiphospholipid Syndrome (APS) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Antiphospholipid Syndrome (APS) market report also covers emerging drugs, current treatment practices, Antiphospholipid Syndrome (APS) market size and share of the individual therapies, current and forecasted Antiphospholipid Syndrome (APS) Market Size from 2017 to 2030 segmented by seven major markets. The report provides a detailed current Antiphospholipid Syndrome (APS) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market. 

Antiphospholipid Syndrome (APS) Market Key Facts

·        To estimate the annual incidence and prevalence of and frequency of mortality associated with APS, Duarte-García et al. (2019) conducted a population-based study. For that, an inception cohort of patients with incident APS in 2000–2015 from a geographically well-defined population was identified based on comprehensive individual medical records review. The investigators estimated the prevalence of 50 per 100,000 population for APS.

·        According to the American College of Rheumatology, Antiphospholipid antibodies are present in 15–20% of all cases of deep vein thrombosis (blood clots) and one-third of new strokes occurring in people under the age of 50.

·        According to American College of Rheumatology (2021) it was reported that antiphospholipid antibody syndrome affects women five times more commonly than men.

·        According to a study conducted by García et. al. (2019), the annual estimated prevalence of antiphospholipid antibody syndrome was 50 (95% CI 42–58) per 100,000 population.

·        According to a study by D'Cruz et. al. (2019), prevalence in the UK peaked at 50 (95% CI 49 – 55) in females in 2011 and 9.8 (95% CI 8.6 – 11.1) per 100,000 in males in 2012.

·        According to a study by Radin et. al. (2020), the prevalence cases of Antiphospholipid antibody syndrome in Italy are 40-50 cases per 100,000 persons and the diagnosis rate of Antiphospholipid antibody syndrome in Italy were 63% in aged of ≤50 years, 39% ≤40 years, and 18% ≤30 years.

·        According to an article by American College of Rheumatology (2021), it was reported that Antiphospholipid antibody syndrome affects women 5 times more commonly than men.

Key Benefits of Antiphospholipid Syndrome (APS) Market Report

• Antiphospholipid Syndrome (APS) market report provides an in-depth analysis of Antiphospholipid Syndrome (APS) Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major markets i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.
• The Antiphospholipid Syndrome (APS) market report will help in developing business strategies by understanding the Antiphospholipid Syndrome (APS) Market trends & developments, key players, and future market competition that will shape and drive the Antiphospholipid Syndrome (APS) market in the upcoming years.
• The Antiphospholipid Syndrome (APS) market report covers Antiphospholipid Syndrome (APS) market growth and current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.
• The report provides a detailed assessment of the Antiphospholipid Syndrome (APS) patient population, market drivers & barriers, Unmet Needs, market opportunities, comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

View Report: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market

Antiphospholipid Syndrome (APS) Market

The Antiphospholipid Syndrome (APS) market outlook section of the report helps to build a detailed comprehension of the historic, current, and forecasted Antiphospholipid Syndrome (APS) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. 

The report gives a thorough detail of Antiphospholipid Syndrome (APS) market trends and shares analysis of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Antiphospholipid Syndrome (APS) Epidemiology

The Antiphospholipid Syndrome (APS) epidemiology section covers insights about historical and current Antiphospholipid Syndrome (APS) patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted Antiphospholipid Syndrome (APS) epidemiology trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

View Report: https://www.delveinsight.com/report-store/antiphospholipid-syndrome-aps-market